Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 15.23 M | 40.21 M | 305.57 M | 176.84 M | |
2022 | -84,195,000 | 35.13 M | 350.05 M | 187.21 M | |
2021 | -155,587,000 | 34.87 M | 398.45 M | 349.22 M | |
2020 | -31,832,000 | 114.73 M | 85.01 M | 77.66 M | |
2019 | 274.41 M | 490 K | 18.54 M | 16.96 M |